Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Denmark-based insulin manufacturer Novo Nordisk is planning to market degludec to first-time insulin users in an attempt to give tough competition to Sanofi-Aventis’ Lantus.
Subscribe to our email newsletter
According to Novo Nordisk, degludec reduces the risk of nocturnal hypoglycemia more than 35% compared with Lantus.
Bloomberg.com has quoted Novo Nordisk chief science officer Mads Krogsgaard Thomsen as saying that the focus is on winning patients as soon as they start using insulin, rather than trying to get them to switch, because diabetics tend to be loyal to a brand.
Novo Nordisk will emphasize that degludec does not need to be injected at the same time each day, unlike Lantus.
The company plans to seek regulatory approval for degludec later this year.
Reportedly, this will be Novo Nordisk’s second attempt to topple Lantus after the 2004 introduction of a similar product, Levemir.